Clinical trials
for patients

The primary objective is to evaluate the safety and tolerability of ZW191 and determine the DMT and DREs of ZW191 in different tumor types.

The main goal of this study, which includes research, is to determine whether the new cancer drug durvalumab given with tremelimumab is safe before surgery. Doctors also want to see if the study drugs cause any delays in surgery due to side effects that participants may experience. Doctors will also analyze the effect that the study drugs have on the tumor and whether the tumor recurs after the combination of the study drugs and surgery.

The objective of the study is to investigate the safety and preliminary antitumor activity of the antibody-drug conjugate OMTX705 (ADC OMTX705 linked to a cytotoxic tubulysin) in patients with advanced or metastatic cancer.

The objectives of this clinical trial are as follows: - To determine the response of patients with CLL/PLLC to treatment with pirtobrutinib (group A) compared to ibrutinib (group B). - To determine the duration of the beneficial effects of treatment with the study drugs (including how long patients live). - To determine safety and tolerability in group A and group B. - To determine how patients in group A fare compared to those in group B.

This study is being conducted to determine: - the safe and tolerable dose of UCART20x22 - the efficacy of UCART20x22 in the treatment of NHLB - how long it takes for the body to eliminate UCART20x22 - how much UCART20x22 reaches the bloodstream This study will also test the safety and effectiveness of different lymphodepletion regimens for patients receiving UCART20x22. Lymphodepletion is a type of therapy that decreases the number of your T cells to make room for the UCART20x22 cells. Three dru...

The objective of this study is to test a new investigational treatment for participants with non-small cell lung cancer.